Jeanne Shaheen US Inactive
SHAHEEN FOR SENATE
NH congressional delegation says state to receive $17M in federal funds for COVID-19 testing
New Hampshire’s congressional delegation said the Granite State is set to receive about $17 million for COVID-19 testing in legislation now on its way to President Donald Trump to be signed into law.
Ad copy
"Shaheen recently called on FEMA to prioritize COVID-19 testing kits for New Hampshire in reaction to the agency’s inadequate response to the state’s needs, which included sending 15 testing machines but only 120 testing kits for the entire state." “In particular, our frontline workers and vulnerable Granite Staters need to be able to access testing quickly which is why this funding can’t come soon enough.”
↗ View in Meta Ad Library (the live creative — image/video/layout)
Performance proxies
| Overall score | 43.2/100 |
| Spend / Reach / Long. / Eff. | 29.2 · 72.4 · 4.4 · 66.6 |
| Spend range | USD 700–799 |
| Impressions | 60,000 – 69,999 |
| CPM (≈ $/1k impr) | USD 11.53 |
| Est. audience size | 5,001 – 10,000 |
| Days live | 17 (2020-05-01 → 2020-05-18) |
| Created | 2020-04-30 |
| Creative variants | 1 body · 1 headline |
| Platforms | facebook, instagram |
| Languages | en |
| Candidate | NH — Jeanne Shaheen |
| Surfaced by | “senate:Jeanne Shaheen” |
🧠 AI analysis
| Issue | healthcare |
| Framing | positive candidate |
| Message type | awareness |
| Emotional appeal | urgency |
| Production tier | semi pro |
| Who pictured | none |
| Symbols | healthcare |
| Call to action | none |
| Standout element | Close-up 3D coronavirus particle image dominating the dark background beneath the bold 'CORONAVIRUS IMPACT' headline |
| Tactic | Borrows credibility from a local TV news article (WMUR) to frame Shaheen as a proactive advocate securing $17M for NH testing, positioning her as effective and responsive while implicitly criticizing FEMA's inadequate handling. |
Where it ran (delivery by region)
| New Hampshire | 100.0% |
Who saw it (delivery)
| 35-44 · female | 13.7% |
| 18-24 · male | 2.5% |
| 65+ · unknown | 0.1% |
| 25-34 · unknown | 0.1% |
| 35-44 · unknown | 0.2% |
| 65+ · male | 4.4% |
| 65+ · female | 3.9% |
| 45-54 · unknown | 0.1% |
| 18-24 · unknown | 0.1% |
| 45-54 · male | 11.4% |
| 55-64 · male | 10.5% |
| 18-24 · female | 2.4% |
| 25-34 · male | 7.5% |
| 55-64 · female | 7.4% |
| 25-34 · female | 8.2% |
| 45-54 · female | 17.1% |
| 35-44 · male | 10.0% |
| 55-64 · unknown | 0.3% |
